key: cord-0980537-fenel4sj
authors: Samaranayake, Lakshman Perera; Seneviratne, Chaminda Jayampath; Fakhruddin, Kausar Sadia
title: Coronavirus disease 2019 (COVID‐19) vaccines: A concise review
date: 2021-05-31
journal: Oral Dis
DOI: 10.1111/odi.13916
sha: ce9a5a26a7926554b87880cf6df4a7eb76ee7ef8
doc_id: 980537
cord_uid: fenel4sj

The development of a successful vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), the agent of coronavirus disease 2019 (COVID‐19), in an unmatched period of ten months, is a tribute to human ingenuity in the face of a vicious pandemic. A return to pre‐pandemic “normalcy” depends on the successful delivery of the vaccine to a majority (~70%) so as to develop herd immunity critical to arrest the community spread of infection. Vaccination against COVID‐19 is particularly important for dentistry as the dental team works in an environment replete with aerosol‐generating procedures (AGP) that facilitate virus spread. Hence, a COVID‐19 vaccine is likely to be an obligatory requirement for the dental practice, and the latest addition to the extensive list of vaccines required for dental professionals for the safe delivery of dental care. Here, we review the currently available major candidate vaccines against SARS‐CoV‐2 and their benefits and risks. These include the vaccines developed on next‐generation platforms (mRNA, DNA, and viral vector vaccines), and the classic platforms (the live‐attenuated virus, and the protein subunit vaccines) The review concludes with a summary of impending issues and challenges facing the provision of COVID‐19 vaccines for all stakeholders in dentistry.

original counterpart (World Health Organization, 2020a), has been a major concern together with the likelihood that they may cause more severe illness. It is now clear that the societal behavior modifications and the antiviral and other therapeutic measures alone are unlikely to rein in the pandemic. The last great hope for its eradication from the face of the earth is most likely through an effective and efficacious global COVID-19 vaccination program.

Remarkably, within a few weeks after the beginnings of the then epidemic in Wuhan, Chinese scientists isolated the viral agent of COVID-19, subsequently named as SARS-CoV-2 (by the World Health Organization), and sequenced its ribonucleic acid (RNA) genetic code and shared it with the world .

This triggered an intense global competition to develop a vaccine against the pandemic virus, with competing vaccine developers using novel technical paradigms and next-generation vaccine platforms, as well as traditional vaccine technology to accelerate their production and win the "vaccine race" (Logunov et al., 2020; Polack et al., 2020; Ramasamy et al., 2020; Zhu et al., 2020) .

Although initially there were over 200 vaccine candidates in the research phase, only about 60 have thus far survived the grueling, drawn-out, and costly vaccine development programs, entailing extensive, triphasic, human trials with thousands of recruits (Dong et al., 2020; Funk et al., 2020; World Health Organization, 2020c) .

Of the COVID-19 vaccines currently in contention, only a handful have thus far been approved for emergency use in Europe, UK, USA, as well as in over 20 other jurisdictions (U.S. Food and Drug Administration, 2020b, 2020d; Logunov et al., 2020; Ramasamy et al., 2020) . A majority of the latecomer vaccines in the pipeline should see the light of day during this year, once they complete their final (Phase 3) human trials, safety and efficacy proven, and approved by the regulatory authorities (World Health Organization, 2020c).

As mentioned, those developing COVID-19 vaccines are currently using both traditional as well as novel, next generating vaccine platforms for this purpose (Poland et al., 2020) . Up to six major vaccine platforms, and combinations thereof, are currently in vogue, and given below is an overview of the major vaccine platforms and their mechanisms (U.S. Food and Drug Administration, 2020c; Keech et al., 2020; Logunov et al., 2020; Polack et al., 2020; Ramasamy et al., 2020; World Health Organization, 2020c; Zhang et al. 2021; Zhu et al., 2020) (Table 1) .

Introducing a new vaccine into the global community is an opportunity to curb the rabid infection and a long-awaited prospect to return to the pre-COVID-19 "normalcy" of delivering dental care.

However, vaccinating a global population is weighed down by a staggering number of issues ranging from supply-chain logistics to myths and fears on vaccine efficacy and side effects leading to socalled "vaccine hesitancy" (syn: anti-vaccination, anti-vax) by a significant proportion of the populace (World Health Organization, 2017 , 2020b . Similarly, the dental team will have to contend with its own share of challenges related to the introduction of a new vaccine developed on hitherto untested vaccine platforms, and the so-called vaccine complacency.

In the final section of this overview, we examine these looming concerns and logistical issues facing both the profession and the public. Nevertheless, first, a rejoinder on the general mechanisms underlying vaccine immunology, followed by a short description of the five major COVID-19 vaccine platforms.

In brief, a vaccine aims to stimulate the body's own protective immune response, mainly antibody-producing B cells, and the enabling T cells (such as cytotoxic T cells) so that, in the event of a future encounter with the specific viral pathogen, then the immune system can quickly recognize the virus, jump into action, kill the invading viral army, prevent the spread of infection, and abort the disease (Samaranayake, 2018) . In the case of vaccines for SARS-CoV-2, the goal is to produce antibodies against the spike (S) protein or the proteins on the receptor-binding domain (RBD) of the spikes (Du et al., 2009; Speiser & Bachmann, 2020 ; Figure 1 ).

It is now well established that the numerous spikes on the viral surface initiate its attachment to the susceptible human cells (via the receptor binding proteins), allowing it to enter the cell and hijack the DNA of the cell, to produce a progeny that will re-infect other cells and spread the infection. Hence, neutralizing the critical functionality of the protruding viral spikes that facilitates viral entry, with the vaccine-induced, preformed antibodies, abetted by the enabling T cells, terminates the infection in its tracks (Du et al., 2009; Grigoryan & Pulendran, 2020) . However, over a prolonged post-vaccination period, the virus-neutralizing antibody level is likely to wane to almost undetectable levels. This is when the vaccine-induced "memory" T-lymphocytes, as well as B-lymphocytes, come into action during a second and subsequent encounter with either the identical virus or its variant progeny (Speiser & Bachmann, 2020;  Figure 2 ).

Antibodies produced by the B cells of the immune system through a vaccination process can vary both in quantity as well as in quality.

In general, antibodies can be divided into two basic types: neutralizing (NAb) and non-neutralizing antibodies (nNAb). The antibodies that block entry of the pathogen into the host cells, and stop the infection, termed neutralizing antibodies, should be distinguished from the binding antibodies or non-neutralizing antibodies (nNAB).

The latter merely binds to the pathogen but does not necessarily interfere with viral entry into the host cells, possibly because they do not interact with the correct structural anatomic region of the virus to disable it. However, binding antibodies play a contributory "accessory role" by signaling the immune cells of the impending viral invasion, after which the virus is processed and destroyed by the recruited immune cells (Schmaljohn, 2013 The neutralizing antibodies ( are also produced simultaneously that can patrol the body for any incoming viruses for months/years and rekindle an identical B-and T-cell response, described above. I: mRNA Vaccines; The vaccine containing mRNA of SARS-CoV-2 with the code for the Spike (S) protein enclosed within lipid particles (to facilitate cell entry) is administered. Once injected, the lipid particles are "ingested" by vaccinees APCs to produce the immune response (as described in (a-d) above). IIa and IIb: Live attenuated and inactivated vaccines; The vaccine containing either the inactivated or the attenuated SARS-CoV-2 is administered to the vaccinee. Once injected, the non-infective virus particles are ingested by the antigen-presenting cells (APC ) to produce the immune response (as described in (a-d) above). III: Protein subunit SARS-CoV-2 vaccines: The vaccine containing the N (nucleocapsid), M (membrane), and S (spike) protein antigens of the virus is administered to the vaccinee. Once injected, the non-infective antigens are ingested by the antigen-presenting cells (APC) (purple) to produce the immune response (as described in (a-d) above). IV: Viral vector-based recombinant vaccines: A non-infectious virus such as an adenovirus, engineered to combine with SARS-CoV-2 Spike (S) protein (recombinant) DNA is used as a vector vehicle in the vaccine. Once injected, the non-infective adenoviruses multiply in host cells, recognised as foreign, and ingested by the antigen-presenting cells (APC; purple) to produce the immune response (as described in (a-d) above); V: DNA vaccines: These vaccines contain pieces of DNA called plasmids found in bacteria to encode spike (S) antigens of SARS-CoV-2. The plasmids with a code to produce S antigens, once ingested by APC are integrated into their nucleus (purple) to produce the immune response (as described in (a-d) above; Figure vaccines, there is still hope, as there are a number of vaccine precedents for epidemic-prone diseases, such as measles, polio, and hepatitis B, where the vaccination process does not produce sterilizing immunity, and yet the spread of community infection has been successfully curtailed (Samaranayake & Anil, 2021) .

Finally, in this context, it is also noteworthy that the `artificial` vaccine-induced "infection" may cause minor symptoms in the vaccinee immediately after vaccination. These, such as soreness of the injection site and mild fever (Kohl et al., 2004) , are rarely as immediately before or after vaccination (as has been reported recently), an outcome that should not be attributed to vaccine failure (CDC, 2021a).

At the time of writing (April 4, 2021), there were 23 vaccines in large scale clinical trials (Phase III), six vaccines in early or limited use and seven vaccines approved for full use (CDC, 2021a). The next section outlines the principles, advantages, and disadvantages of the five major vaccine platforms, details of minor groups such as repurposed BCG vaccines are not provided here for the sake of clarity.

First, the three major classic vaccine platforms, live attenuated virus, whole inactivated virus, and virus-like particle/subunit vaccines are described, followed by the next generation platform vaccines mRNA, DNA, and viral vector vaccines (Tables 1 and 2, Figure 2 ). These vaccine platforms are decades old, and the vaccines essentially contain multiple antigenic components derived from the attenuated live viruses, which are immunogenic but not infectious . The advantages include proven technology and long-lasting and robust immunogenicity, including stimulation of toll-like receptors. A major drawback of this platform is the need to handle live viruses during manufacture *All vaccines essentially need two repeated doses to achieve optimal seroconversion and are injected intramuscularly, usually the arm.

components are retained. The technology used in this platform is also decades old and proven. Due to the presence of the whole virus with a multiplicity of surface antigenic components, these vaccines induce a diverse immunologic response . Nevertheless, they are less reactogenic and produce a weaker immune response than live attenuated vaccines. The manufacturing process of both the live attenuated and inactivated vaccine preparations entail handling live virus preparations, which adds to their complexity. This contrasts with other vaccine platforms described below that use viral components, as opposed to the whole viruses, as the active ingredient of the vaccine . Examples of inactivated viral vaccines currently in use are inactivated poliovirus vaccine (IPV or Salk variant) and the hepatitis A vaccine (Sanders et al., 2014) , Table 2 . (Table 2) , mainly the S or RBD proteins that act as antigens once injected into a vaccinee, (Figure 1 ). As live virus handling is not required, subunit vaccine manufacturing process is safer and simpler (Romero-Maldonado et al., 2014) . However, one disadvantage is they often require effective adjuvants to obtain a more robust immune response, and on occasions, the adjuvants may cause strong allergic reactions in vaccinees . Nil SARS-CoV-2 and is thought to induce a more robust cellular immune response than the recombinant protein vaccines .

Adenovirus, retroviruses, and vaccinia viruses are traditionally used as carrier vehicles in viral vector vaccines (Rauch et al., 2018) .

For example, in the case of the newly approved Oxford-AstraZeneca vaccine, the vector virus used is a modified version of a chimpanzee adenovirus, known as ChAdOx1 which can enter human cells but cannot replicate within them (Ramasamy et al., 2020) , Viral vector vaccine platform technology is not new and have been used for many years in the field of gene therapy. The proven experience so garnered is an advantage over the newer platforms such as mRNA vaccines described below. They are also safe as weak virus vectors, due to gene deletion, do not replicate within the cells once injected, leading to a slim, if any, risk of chromosomal integration (Table 2 ). One drawback of such vaccines, in general, is that they may not be suitable for immunocompromised subjects, as most of them are likely to have been previously exposed to adenoviruses and may have pre-existing immunity to them (Gray & Erdman, 2018) Such immunity, including the presence of antibodies against adenoviruses, may impedes the entry of the "vaccine strain" of the adenovirus, (i.e., the active component of the vaccine) into the vaccinees/ host cells thereby minimizing or aborting the vaccine efficacy (Gray & Erdman, 2018) . One way to circumvent this is to utilize animal adenovirus vectors, which can gain entry into human cells but are not human pathogenic. Hence, the Oxford-AstraZeneca COVID-19

vaccine utilizes a chimpanzee adenovirus as a vector (Ramasamy et al., 2020) .

Examples: Moderna, Pfizer-BioNTec (Others in the pipeline:

CureVac/Bayer and Imperial College London). This is one of the newest yet simplest methods available to insert specific viral genes, such as the spike (S) protein gene of SARS-CoV-2, to human cells so as to produce antibodies against them ( Figure 2 . This technology entails artificial synthesis of messenger RNA of the virus in the laboratory (using a known RNA sequence to produce S or RBD proteins) and incorporating these within lipid nanoparticles (LNP) to protect the fragile RNA as well as to increase the `transfection efficacy.' The lipid nanoparticles act as the transportation vehicle for the surreptitious transfer of the RNA into the immune cells (Schlake et al., 2012) . The lipid nanoparticles protect the very fragile RNA strands and prevent their destruction until they reach the active site in the receptor cells (Zhang et al., 2019) ,

Once injected, as a vaccine, the lipid droplets are "ingested" by vaccinees immune cells. The oily/lipid coat is gradually destroyed, exposing mRNA, after which the protein-making machinery of the cell is then instructed to produce viral proteins (i.e., S or RBD antigens), which are either presented on the cell surface or released into the bloodstream. When the B or T cells encounter these so-called "antigen-presenting cells" with S or RBD antigens, they produce antibodies while simultaneously activating the killer T cells (Jackson et al., 2020; Polack et al., 2020; Sahin et al., 2020) . The immune system is now forearmed to attack the invading virus, as it already has antibodies and the T cells to kill the invader (Figure 2 ).

The significant advantages of mRNA vaccines are their safety, rapidity, and flexibility of design and production (Pardi et al., 2018) .

As the production process does not entail using either live or attenuated viral vectors, these vaccines are simple to develop and manufacture. Moreover, the strong and quick humoral and cell-mediated antiviral responses (over 90%) are truly spectacular, compared with vaccines, such as the seasonal flu vaccines with approximately 50%-60% efficacy (Zhang et al., 2019) . Finally, as mRNA is not inserted into the (DNA) nuclear material of the immune cells, but slowly destroyed in the cellular cytoplasmic vesicles, there is no likelihood for insertional mutagenesis (Jackson et al., 2020; Sahin et al., 2020) .

Despite the above advantages, the biggest drawback of these vaccines is their fragility. The formulations require ultra-cold chain requirements (−70 0 C) for longevity and stability due to RNA that is easily destroyed (U.S. Food and Drug Administration, 2020a). Hence, the widespread deployment of these vaccines in resource-poor jurisdictions is highly questionable, as DNA vaccines are far superior for such regions. (For, DNA is highly stable and may be extracted even from remnants of prehistoric animals). Finally, in this context, mRNA vaccines have only been used previously for cancer therapy and not to prevent infections (Pardi et al., 2018) . Hence, the long-term adverse effects of viral RNA vaccines, if any, are not known as yet.

Some of the side effects seen in mRNA vaccines were identical to those seen with traditional vaccines. They included pain and inflammation at the injection site, fatigue, chills, headache, and myalgia. However, some have reported systemic adverse effects that were more severe and frequent after the second vaccination (Jackson et al., 2020) . In order to produce the S or RBD proteins, these plasmids need to enter (jump into) the nucleus of the antibody-producing B cells, and plasmids have the intrinsic ability to do so (Liu, 2019, Figure 2 ).

The significant advantages of this genre of DNA vaccines include, not necessitating live virus handling during preparation, and the possibility of freeze-drying and long-term storage and transportation at ambient temperatures (as opposed to extremely fragile mRNA vaccines above) . None of the plasmids derived DNA vaccines have been released for general use as yet, although some are in final, phase 3 trials. Currently, DNA vaccines are approved only for use in veterinary practice ( (Zimmer et al., 2021) . Once the data on vaccine efficacy from these trials are released, vetted and approved, by various regulatory authorities, it is highly likely that the vast majority of these new vaccines will be released for general administration before the end of 2021. It is likely that there will be a glut of COVID-19 vaccines of various descriptions, by the end of 2021 and the bottle necks in vaccinating the whole world population are likely to be the delivery and supply chain logistics to remote regions of the world, and the vaccine hesitancy of a substantial proportion of the population, as described in the next section.

The final section of the review addresses salient key issues appertaining to COVID-19 vaccines, vaccinations, and dentistry, with concluding perspectives.

A primary duty and a major obligation of a dental professional is to deliver care in a healthy and safe environment for the patients and the attending co-workers. A core component of such risk mitigation is to prevent the spread of infectious hazards within the dental clinic by implementing standard infection control measures in dentistry (CDC, 2020; Clementini et al., 2020; Izzetti et al., 2020; Li et al., 2020; Samaranayake, 2018; Volgenant et al., 2020) , and enshrined therein is a major stipulation for immunization of all clinical practice personnel against a range of readily transmissible infections. Accordingly, the staff needs to be protected from a number of bacterial and viral infections, through a regimented vaccination procedure, as a buffer against occupationally acquired infections such as hepatitis B and seasonal influenza (World Health Organization, 2015; Table 2 ; last column). It is highly likely that the COVID-19 vaccine will now be the newest addition to this extensive list of vaccines obligatory for dental care workers to conduct safe dental practice.

In this context, universities and similar establishments that deliver dental education for undergraduates and postgraduates need to consider how best to manage COVID-19 vaccination requirements and develop necessary guidelines, as in the case of the current hepatitis B vaccination regimen stipulated for such teaching institutions.

In future, all students may be required to produce COVID-19 immune sufficiency certificates (either electronic or hard copy) at periodic intervals prior to attending college, depending on factors that are yet to be determined. These obligatory requirements should be applied across the board to all academic staff and other clinical or non-clinical support personnel, as necessary for the benefit of all stake holders including the patients attending such establishments (Khalifa et al., 2021) .

We are in the first phase of the COVID-19 vaccination program, and it is unclear to what extent the foregoing scenarios will transpire in the future. There are still many questions than answers on COVID-19 vaccines, both related to vaccines in general and dentistry specifically, such as the following: How long will vaccine immunity last and the necessity of periodic booster vaccines, especially for the dental team? What are the correlates of protective immunity following vaccination? Does clinical dentistry increase the risk for infection to patients and the dental staff? Whether the dental/oral pathology visits, which may have been repeatedly delayed or postponed due to the pandemic, impact patients' outcomes due to late screening, and diagnosis (e.g., oral cancer and other progressive oral diseases), and finally, in view of the lasting impact of the pandemic, the renewed and urgent requirement for developing oral telemedicine.

It will take a few years before we have answers to all these questions. Until then, as responsible health care providers, the dental community has a duty and an obligation to keep abreast of the dynamic developments in the COVID-19 vaccine ecosystem, particularly the adverse and beneficial effects across the spectrum of vaccines delivered. However, it is crucial for the community to comprehend that COVID-19 vaccines are but a single arm in the overall public health response to the pandemic, and also the critical necessity to maintain other public health preventive measures such as wearing of masks, social distancing, and maintaining scrupulous hand and personal hygiene (CDC, 2021c). Vaccines are termed the tugboats of preventive health, and in the case of the COVID-19 pandemic, the currently available raft of vaccines and the newer, impending arrivals in the final stages of approval appear to be the raft of tugboats that will drag the humanity out of this perfect, viral storm.

The authors declare no conflict of interest.

Summary of infection prevention practices in dental settings

About COVID-19 Vaccination

Emerging SARS-CoV-2 Variants

How to protect yourself and others

Aerosol transmission for SARS-CoV-2 in the dental practice. A review by SIdP Covid-19 task-force

A systematic review of SARS-CoV-2 vaccine candidates

The spike protein of SARS-CoV-a target for vaccine and therapeutic development

A Snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic

Adenovirus vaccines. Plotkin's Vaccines

The immunology of SARS-CoV-2 infections and vaccines

A perspective on dental activity during COVID-19: The Italian survey

An mRNA vaccine against SARS-CoV-2 -preliminary report

Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine

Dental pedagogy in the new normal COVID-19 Era: A transition template of teaching protocols

Will SARS-CoV-2 infection elicit long-lasting protective or sterilising immunity? Implications for vaccine strategies (2020)

Fever after immunization: Current concepts and improved future scientific understanding

Broadly neutralizing antibodies in HIV-1 treatment and prevention

Facial protection in the era of COVID-19: A narrative review

A comparison of plasmid DNA and mRNA as vaccine technologies

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia

How disease affected the end of the bronze age. A history of disease in ancient times: More lethal than war

mRNA vaccines -a new era in vaccinology

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

SARS-CoV-2 vaccine development: Current status

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A singleblind, randomised

New vaccine technologies to combat outbreak situations

Plant-based vaccines against Influenza. In Genetically engineered plants as a source of vaccines against wide spread diseases

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Essential microbiology for dentistry

COVID-19 and dentistry: Perspectives of an unfolding pandemic

Understanding COVID-19 vaccines, and Immunity

COVID-19 Vaccines and Dentistry

Inactivated viral vaccines

Developing mRNA-vaccine technologies

Protective antiviral antibodies that lack neutralizing activity: Precedents and evolution of concepts

COVID-19: Mechanisms of vaccination and immunity

Food and Drug Administration (FDA). (2020a). FDA briefing docu-mentforCOVID-19vaccineEUAbyPfizer

Food and Drug Administration (FDA). (2020b). ModernaCOVID-19 Vaccine EUA Letter of Authorization

Food and Drug Administration (FDA). (2020c). Moderna COVID-19 vaccine FDA briefing document

PfizerCOVID-19EUA Letter of Authorization Reissued

Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. FDA VRBPAC-02.26.21-Meeting-Briefing-Document

Infection control in dental health care during and after the SARS-CoV-2 outbreak

The genetic sequence, origin, and diagnosis of SARS-CoV-2

The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation

Vaccine-preventable diseases and vaccines. International Travel and Health -CHAPTER

Vaccines-and-trust. World Health Oraganization (WHO)/Europe

SARS-CoV-2 Variants. Disease Outbreak News, World Health Organization

Vaccine management and logistics support. World Health Organization (WHO)

Coronavirus disease 2019 (COVID-19):situationreport

Advances in mRNA vaccines for infectious diseases

Progress and prospects on vaccine development against SARS-CoV-2. Vaccines

Safety, tolerability, and immunogenicity of an inactivated SARSCoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A doseescalation, open-label, non-randomised, first-in-human trial

-2. How to cite this article: Samaranayake LP, Seneviratne CJ, Fakhruddin KS. Coronavirus disease 2019 (COVID-19) vaccines: A concise review